Summary
Clinical evaluation of circulating tumor cells (CTCs) in head and neck cancer patients demonstrated a strong association between CTC burden and overall disease severity. Elevated CTC levels in peripheral blood were linked to advanced tumor stages and increased tumor burden, highlighting their relevance in disease progression. As a minimally invasive liquid biopsy approach, CTC detection provides valuable insights into tumor dynamics and metastatic potential without the need for repeated tissue biopsies. Integration of CTC-based biomarkers into clinical workflows supports improved prognostic assessment, personalized treatment planning, and continuous disease monitoring in head and neck oncology.
Read Abstract
Key Findings:-
- Elevated CTC counts are associated with advanced-stage disease and higher tumor burden.
- CTC enumeration provides insights into metastatic potential and tumor progression.
- Blood-based CTC detection serves as a non-invasive alternative to tissue biopsy.
- CTC levels can function as prognostic biomarkers for clinical outcome prediction.
- Longitudinal CTC monitoring supports real-time assessment of disease dynamics.